Lytix Biopharma will together with Mikael Pittet, from Massachusetts General Hospital and Harvard Medical School, present data at the AACR Annual Meeting to be held in Chicago April 14-18th 2018.
The conference is the world largest cancer research conference with more than that 20.000 leading scientists and a large number of pharmaceutical companies attending, and the mission is to prevent and cure cancer through research, education, communication and collaboration.
The title of the presentation is “Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo- and immunotherapeutic treatments” and will reveal the mechanism behind LTX-315 treatment and the transition from a “cold” to “hot” tumor microenvironment which is a prerequisite for successful immunotherapy.